Method for blocking HIV entry into dendritic cells by inhibiting sialoadhesin-sialyllactose binding interactions with gangliosides
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 17, 2017
Issued Date -
N/A
app pub date -
Dec 17, 2012
filing date -
Dec 22, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2012 Application Filing Year
- A61K Class
- 11964 Applications Filed
- 9694 Patents Issued To-Date
- 81.03 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 8 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Apr 17, 2025 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Apr 17, 2029 |
